Eli Lilly's orforglipron is not currently approved, but the company is aiming for regulatory submission in 2026 [1].
When might orforglipron be available to patients?
Orforglipron is a novel oral medication for weight management that Eli Lilly is developing. The company anticipates submitting it for regulatory approval in 2026 [1].
What is orforglipron and how does it work?
Orforglipron is an investigational oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. It is designed to mimic the action of the GLP-1 hormone, which plays a role in regulating appetite and food intake [2, 3]. Unlike injectable GLP-1 agonists, orforglipron is taken orally [3].
What clinical trials are underway for orforglipron?
Eli Lilly is conducting Phase 3 clinical trials for orforglipron in adults with obesity or overweight and at least one weight-related comorbidity [1]. These trials are evaluating the drug's efficacy and safety [1].
How does orforglipron compare to other weight-loss drugs?
Orforglipron is a potential competitor to existing and pipeline weight-loss medications. While injectable GLP-1 agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) are currently the standard of care for significant weight loss, orforglipron offers an oral alternative [2, 3]. Its development in an oral formulation could appeal to patients seeking a less invasive treatment option [3].
What are the potential risks and side effects of orforglipron?
As with any medication, orforglipron carries potential risks and side effects. Clinical trial data will ultimately define the safety profile of the drug. Common side effects associated with GLP-1 receptor agonists, in general, can include gastrointestinal issues such as nausea, vomiting, and diarrhea [4].
What is the patent status for orforglipron?
Information regarding specific patents for orforglipron can be found through patent databases. DrugPatentWatch.com tracks patents for pharmaceutical products [5].
Who else is developing weight-loss medications?
The market for weight-loss medications is competitive, with several pharmaceutical companies researching and developing new treatments. Eli Lilly's work on orforglipron places it among other major players in this therapeutic area [2, 3].
---
Sources:
[1] Eli Lilly and Company. (n.d.). Orforglipron. Retrieved from https://www.lilly.com/news/blog/patient-stories/orforglipron-weight-management
[2] DrugPatentWatch.com. (n.d.). GLP-1 Receptor Agonists. Retrieved from https://drugpatentwatch.com/blog/glp-1-receptor-agonists/
[3] DrugPatentWatch.com. (n.d.). Orforglipron. Retrieved from https://drugpatentwatch.com/drugs/orforglipron
[4] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Weight-Loss Medications. Retrieved from https://www.niddk.nih.gov/health-information/weight-management/adult-weight-loss-medications
[5] DrugPatentWatch.com. (n.d.). Drug Patents. Retrieved from https://drugpatentwatch.com/drugs